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Introduction
Researchers and clinicians have long recognized that understanding patient perceptions of their health provides a fuller appreciation of the range of symptoms and life impact of chronic conditions. Yet, until recently it was also believed that the responsibility for defining outcomes and creating measures rested largely with health professionals. Beginning in the late 1970's, select groups began to acknowledging that beyond serving solely as research subjects, patients had an important view to consider. However, the idea that patients could offer valuable input as research partners only gained traction when people with HIV/AIDs began insisting that they had a right to help identify research priorities and outcomes (1) . By the millennium, several scientific organisations (e.g., Outcome Measures in Rheumatology --OMERACT) championed the necessity of always involving people living with health conditions as collaborative research partners.
Fifteen years later, much has been accomplished and several approaches have emerged as a growing number of researchers and organizations seek to improve research by directly engaging patients. growing interest, evidence for the impact of patient engagement on outcomes research, measurement development, and healthcare decision-making is limited (2) (3) (4) (5) (6) . Further, little guidance is available for approaches that work well, for whom, and in what context (7) .
To further understanding of how to integrate patients into all aspects of outcomes research, including PRO development, we describe and discuss the experiences of three patient-centered outcomes research (PCOR) stakeholders: a clinical research leader, a patient research partner (PRP), and a representative of a PCOR funder. These real-world examples illustrate different approaches and levels of PRP integration, the added value PRPs contribute to outcomes research, and highlight lessons learned to optimize engagement. Although each organization represented has created organizationspecific principles and recommendations for engagement, a set of basic guidelines for optimizing success of research partnerships, generalizable to outcomes research, emerges across the groups.
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A Researcher's Experience
Professor John Kirwan (Consultant Rheumatologist, Bristol UK), an experienced clinical researcher working to improve the lives of people with rheumatic diseases, has integrated patients into the international research organization OMERACT. He was responsible for guiding and implementing the current policy in OMERACT that states outcome measures can only be adopted if patients have participated in their development (8, 9) .
OMERACT is an independent initiative of international health professionals which uses a datadriven, multi-stakeholder consensus process to identify and improve outcome measures in musculoskeletal conditions (10) . Since 1990, OMERACT has served a critical role developing and validating rheumatology outcome measures. Evidence supporting existing PROs as primary outcomes or the need to develop new PROs is presented at biennial meetings. There is detailed small group discussion followed by plenary summaries. All participants, including the PRPs are involved in decision- As experience with patient engagement accumulated, the benefits were more widely appreciated, valued, and patients were incorporated into all activities (8) . Today, all OMERACT working groups include PRPs as they undertake research between biennial meetings; groups presenting during plenaries must fund at least one PRP to attend. At meetings, patients have full voting rights and participate in all sessions. Attendance at several meetings has allowed some patients to become very familiar with the process, and they now occupy a 'halfway house' between researchers and patients. Patients continue to provide their experience-based perspective, a perspective researchers do not have; PRPs involved over time are able to understand more, and are more comfortable with the language of, and constraints imposed by, the research process. Indeed, one PRP (MdW) undertook doctoral studies and became a researcher in his own right.
These changes have had a large impact. Researchers already committed to doing the best for their patients, recognize the benefits of including patients when conceiving, designing, carrying out research and disseminating results (11) . Perhaps the most dramatic consequence has been the refocusing of the research community on fatigue in RA. Initially, fatigue was omitted from the 1992 core outcome set. PRPs highlighted how fatigue affects everyday life, stimulating research to quantify its impact and demonstrate how fatigue assessment adds understanding of trial outcomes. As a result, OMERACT now endorses fatigue as a necessary assessment in all future RA trials (12) (13) (14) .
By 2016, the involvement of PRPs (about 10% of conference participants) is now so pervasive that it is difficult to separate their contribution from those of researchers and other stakeholders. However, achieving this required a sustained effort by organisers to ensure patient involvement over successive meetings. Important lessons have been learned. A commitment to funding PRP participation in working groups and conference attendance was an early step, as was increasing the educational support and training given to patients at conferences. For example, each day, organizers of the next day's sessions meet with PRPs to explain how they came to be on the program, what they hope to achieve, what patients should look for, and how they might best contribute to small group discussions. This is an example of the type of research training that can benefit partnerships by ensuring that patients understand the research agenda and goals and can feel comfortable in the discussions while recognizing the unique perspective they bring.
Within OMERACT, PRPs organize training to prepare new PRPs and update experienced ones.
At OMERACT 2016, experienced PRPs held an introductory webinar and half-day session for new participants immediately before the meeting. They provided a glossary explaining terms such as RCT and validity. (The glossary has proven so popular that all attendees now receive a copy.) Lay summaries of each session are included in the program.
Over 16 years, PRPs and researchers have learned new skills and OMERACT has published recommendations for meaningfully engaging PRPs in all working groups (15) . The OMERACT experience highlights the importance of education and training to support successful partnerships, and how attitudes, of researchers, PRPs, and organizations create a culture in which partnerships can thrive.
A PRP's Experience
Maarten de Wit lives with psoriatic arthritis (PsA), and is a PRP. He worked with the European League Against Rheumatism (EULAR) to create recommendations for patient engagement in scientific projects (16) which helped guide development of a new measure in PsA. Because there was no existing measure reflecting the patient perspective (17, 18) , EULAR facilitated the development and validation of the Psoriatic Arthritis Impact of Disease score (PsAID) (19) . PsAID developers now use this work as a case study of a successful patient-research partnership in developing a new outcome measure (20) .
This project serves as a best practice exemplar because it demonstrates multiple forms of PRP participation throughout PRO development. Different PRPs were involved in subsequent phases, contributing in diverse ways, and at all levels. This example also demonstrates the role of research team attitudes in creating an environment that supports partnership. Below is a summary of the range of activities that PRPs undertook.
Steering committee. Two PRPs were part of the steering group, participating in all discussions and decision-making.
Foundational qualitative work. Initially, PRPs from 11 European countries participated in a meeting (led by a nurse researcher and patient) to identify life impact domains accordance with EULAR recommendations (Table 1) (16) . PRPs were recruited through the clinics of participating physician-researchers to identify those who could travel, had relevant skills, and were interested in collaborating on this project.
Questionnaire development, refinement, and validation. 139 patients prioritized 16 life-impact domains, and 65 patients provided feedback on item wording, and offered alternative terms when translating the questionnaire into different languages (21) . Initial validation included 499 new patients from 11 countries who completed questionnaires and underwent a clinical examination.
While there was agreement on many things, there was also some discordance. For example, patients strongly favored including coping questions as this was viewed as an important indicator of poorly-controlled disease. There was debate about three items that queried embarrassment/shame, social participation, and depression. Many of the professionals and some patients questioned the added value of asking all patients in a clinical trial about the psychosocial consequences of PsA; others argued that they were important for some, and should be part of patient-physician conversations. Given that the the initial objective was to develop a tool appropriate for both clinical trials and practice, the team developed two versions: a 9-item PsAID focusing on measurement objectives to meet the needs of trialists, and a 12-item version for clinical practice as many patients want the psychological impact of living with PsA to be part of broader conversations. Most researchers agreed that involving patients was essential when developing PROs.
Evidence from EULAR and others suggests that the investigators play a key role in successfully integrating PRPs into projects and eliciting meaningful contributions (22) (23) (24) . As with OMERACT, EULAR PRPs received education and support to better understand the research process, fully participate in meetings, and confidently voice opinions, while still providing their unique experience-based perspective.
PRPs sessions were held before team meetings. A glossary helped them learn about research (e.g., the experimental method). Project-specific education included: 1) Explaining the goals and process of PRO processes adopted (methods adopted; levels of engagement; stages of the research during which patients were involved as research partners); and outcomes. Careful documentation of these aspects can contribute to the development of a knowledge-base for engaged research.
Challenges in patient-research partnerships. PRPs should possess a set of core competencies that align with the project's objectives and process but considerable uncertainty remains around identifying these. The reality of limited time must be faced, as time spent identifying and developing productive relationships with PRPs too often represents "unfunded activities." OMERACT allocated funds and personnel to support patient engagement from the initiation of working groups. As a funder, PCORI recognizes that meaningful engagement of patients in research may add time and costs to research projects, and application reviewers are made aware of the different resources and needs that this type of research can produce, relative to non-engaged research models. The cultural impact of PRPs also warrants evaluation, including attention to positive and negative consequences for researchers and PRPs.
Conclusions
We have described three ways that outcomes research was improved by involving PRPs.
Supporting patients in their role as full research partners enables them to contribute their experiential knowledge and help ensure results are relevant and address patient needs, preferences and priorities.
Organisations such as ISPOR, ISOQOL, OMERACT, EULAR, PCORI and others recognise the benefits and mandate that patient partners are incorporated into their structure and function. Within ISPOR, the Patient-centered SIG is poised to facilitate this (http://www.ispor.org/sigs/patientcentered/pc_engagementinresearch.aspx). As PCOR spreads to other organizations, it will be important to collect evidence on the impact of engaging PRPs in research and to identify ways to facilitate it across disciplines. While views about the value of patient engagement are not based on controlled trials (e.g., comparing engagement vs no engagement), recognizing the value of patient engagement can both reflect and drive the cultural shift among researchers. Table 1 
